Trifluridine/Tipiracil is named as an intervention in 25 current clinical trials in our China, USA, UK and India registers. 15 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AbbVie (2). The most-studied condition is Colorectal Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Colorectal Cancer | 7 |
| Metastatic Colorectal Cancer | 3 |
| Advanced Solid Tumors | 3 |
| Colorectal Cancer Metastatic | 2 |
| Metastatic Colorectal Cancer (CRC) | 2 |
| TAS 102 | 2 |
| Gastroesophageal Cancer | 1 |
| Refractory Metastatic Colorectal Cancer | 1 |
| Cancer | 1 |
| Solid Tumor | 1 |
| Locally Advanced Solid Tumor | 1 |
| Advanced Microsatellite Stable Colorectal Cancer | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Gastroesophageal Adenocarcinoma | 1 |
| Rectal Cancer | 1 |
| Colorectal Cancer Recurrent | 1 |
| Colo-rectal Cancer | 1 |
| Third-line and Beyond Therapy | 1 |
| Bevacizumab | 1 |
| Gastric Cancer | 1 |
| Gastroesophageal Junction Cancer | 1 |
| mCRC | 1 |
| ESCC | 1 |
| Radiotherapy | 1 |
| EFS | 1 |
| pCR Rate | 1 |
| Gastric (Stomach) Cancer | 1 |
| Biological Therapy | 1 |
| Immunotherapy | 1 |
| Lead sponsor | Trials |
|---|---|
| AbbVie | 2 |
| Sun Yat-sen University | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| Merck Sharp & Dohme LLC | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Delcath Systems Inc. | 1 |
| Regeneron Pharmaceuticals | 1 |
| Parabilis Medicines, Inc. | 1 |
| Gilead Sciences | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Ruijin Hospital | 1 |
| Qilu Hospital of Shandong University | 1 |
| AstraZeneca | 1 |
| The Second Affiliated Hospital of Shandong First Medical University | 1 |
+ 7 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 19 | 11 |
| Clinical trials in USA | 10 | 6 |
| Clinical trials in UK | 3 | 1 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
25 current trials in our China, USA, UK and India registers name Trifluridine/Tipiracil (also registered as TAS-102) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 15 of the 25 trials are recruiting: 11 with sites in China, 6 with sites in USA and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AbbVie (2), Sun Yat-sen University (2), Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) and Merck Sharp & Dohme LLC (1), among 22 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trifluridine/Tipiracil works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trifluridine/Tipiracil works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trifluridine/Tipiracil (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.